Tag: immunotherapy

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Gastrointestinal Cancer Market During 2026–2030?

The gastrointestinal cancer market has expanded swiftly in recent years. It is anticipated to increase from $27.05 billion in 2025 to $30.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.1%. This historic growth can be attributed to the increasing prevalence of gastrointestinal cancers, the expansion of diagnostic imaging capabilities, rising awareness of early cancer detection, growth in oncology drug development, and improved access to cancer treatment facilities.

The gastrointestinal cancer market is projected for significant expansion in the coming years, anticipated to reach a valuation of $47.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This growth over the forecast period can be attributed to increasing investments in personalized oncology, the growing adoption of biomarker-based diagnostics, the expansion of immuno-oncology pipelines, the rising use of minimally invasive diagnostics, and an increase in healthcare spending for cancer care. Key trends anticipated during this period encompass the increased adoption of targeted gastrointestinal cancer therapies, the growing application of molecular diagnostics, a greater emphasis on immunotherapy combinations, the expansion of early cancer screening initiatives, and enhanced integration of precision medicine.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

What Core Drivers Are Transforming The Gastrointestinal Cancer Market?

The increasing acceptance of targeted therapies is anticipated to stimulate future expansion in the gastrointestinal cancer market. These treatments precisely inhibit cancer cell proliferation by acting on specific molecular targets, thereby minimizing damage to normal, healthy cells. Targeted therapies are specifically designed to interact with particular molecular pathways or genetic mutations that drive a disease, especially within cancer. Unlike traditional treatments such as chemotherapy, which indiscriminately attack both healthy and diseased cells, targeted therapies concentrate on the unique characteristics of a patient’s condition. For gastrointestinal (GI) cancer, these therapies function by targeting specific genes or proteins that control tumor growth, leading to precise and effective treatment. This results in superior outcomes with fewer adverse effects than conventional chemotherapy. For instance, in July 2023, as per the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II at the end of quarter one (Q1) 2023, with this total increasing by 5% to reach 260 by the end of quarter two (Q2). Consequently, the growing integration of targeted therapies is actively fueling the expansion of the gastrointestinal cancer market.

How Is The Gastrointestinal Cancer Market Structured Across Different Market Segments?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

What Trends Are Shaping The Gastrointestinal Cancer Market Structure?

Leading companies within the gastrointestinal cancer market are concentrating on creating sophisticated solutions, including monoclonal antibody treatment, with the aim of boosting patient survival rates and lessening adverse effects associated with treatment. Monoclonal antibody treatment functions by utilizing antibodies produced in laboratories that accurately pinpoint and attach to cancer cells, thereby aiding the immune system in identifying and eradicating them. As an illustration, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical firm, introduced VYLOY (zolbetuximab) when combined with fluoropyrimidine- and platinum-containing chemotherapy, after receiving authorization from the European Commission. This therapy serves as a first-line option for adults diagnosed with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, specifically those whose tumors display claudin 18.2 (CLDN18.2) expression. The aforementioned approval positions VYLOY as the initial and exclusive treatment in the European Union targeting CLDN18.2, a biomarker present in approximately 38% of these patients, a finding substantiated by positive outcomes from the SPOTLIGHT and GLOW clinical trials.

Which Organizations Are Operating Within The Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Access The Complete Gastrointestinal Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Region Accounts For The Highest Share Of The Gastrointestinal Cancer Market?

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gastrointestinal Cancer Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2026, By The Business Research Company

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Gastroparesis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Barretts Esophagus Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/barretts-esophagus-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Gastrointestinal Cancer Market Over The 2026–2030 Period?

The gastrointestinal cancer market has experienced rapid growth in recent years. It is forecast to expand from $27.05 billion in 2025 to $30.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. This historical growth can be linked to several factors, including the increasing occurrence of gastrointestinal cancers, the development of diagnostic imaging technologies, greater public awareness for prompt cancer detection, progress in oncology drug creation, and improved accessibility to cancer care facilities.

The gastrointestinal cancer market is projected to experience substantial expansion in the coming years. It is set to reach $47.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This anticipated growth during the forecast period is primarily driven by factors such as greater investments in personalized oncology, the increasing embrace of biomarker-based diagnostics, the broadening of immuno-oncology pipelines, the expanding application of minimally invasive diagnostics, and a rise in healthcare spending allocated to cancer treatment. Key trends anticipated during the same period encompass the growing acceptance of targeted GI cancer therapies, an uptick in the utilization of molecular diagnostics, an intensified focus on immunotherapy combinations, the broadening of early cancer screening initiatives, and the improved incorporation of precision medicine.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Gastrointestinal Cancer Market?

The increasing embrace of targeted therapies is projected to fuel the expansion of the gastrointestinal cancer market moving forward. These treatments function by precisely hindering cancer cell proliferation through interaction with specific molecular targets, thereby minimizing harm to normal, healthy cells. Targeted therapies are designed to intervene in particular molecular pathways or genetic mutations that drive disease, especially in cancer. Unlike conventional treatments such as chemotherapy, which attack both healthy and diseased cells indiscriminately, targeted therapies concentrate on the distinct characteristics of a patient’s condition. For gastrointestinal (GI) cancer, these therapies act on specific genes or proteins that regulate tumor growth, offering precise and effective treatment. This yields superior outcomes with fewer side effects compared to traditional chemotherapy. For instance, in July 2023, as reported by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, the number of gene therapies in Phase II stood at 247 at the end of quarter one (Q1) 2023, subsequently rising by 5% to reach 260 by the end of quarter two (Q2). Thus, the growing adoption of targeted therapies is indeed propelling the growth of the gastrointestinal cancer market.

Which Segment Types Are Examined In The Gastrointestinal Cancer Market Segment Study?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

Which Trends Are Shaping The Gastrointestinal Cancer Market?

Leading companies in the gastrointestinal cancer market are concentrating on developing advanced solutions, such as monoclonal antibody treatment, to enhance patient survival rates and mitigate treatment-related adverse effects. Monoclonal antibody treatment involves the use of laboratory-produced antibodies designed to precisely identify and attach to cancer cells, thereby assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, following approval from the European Commission. This therapy is intended as a first-line treatment for adults diagnosed with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval positions VYLOY as the inaugural and sole therapy available in the European Union that targets CLDN18.2, a biomarker found in approximately 38% of these patients, supported by encouraging clinical trial data from the SPOTLIGHT and GLOW studies.

Which Players Are Part Of The Competitive Landscape Of The Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Get The Full Gastrointestinal Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Region Leads The Gastrointestinal Cancer Market In Terms Of Market Share?

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastrointestinal Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2026, By The Business Research Company

Colorectal Cancer Molecular Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Colorectal Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Gastrointestinal Cancer Market Over The 2026–2030 Period?

The gastrointestinal cancer market has experienced rapid growth in recent years. It is forecast to expand from $27.05 billion in 2025 to $30.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. This historical growth can be linked to several factors, including the increasing occurrence of gastrointestinal cancers, the development of diagnostic imaging technologies, greater public awareness for prompt cancer detection, progress in oncology drug creation, and improved accessibility to cancer care facilities.

The gastrointestinal cancer market is projected to experience substantial expansion in the coming years. It is set to reach $47.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This anticipated growth during the forecast period is primarily driven by factors such as greater investments in personalized oncology, the increasing embrace of biomarker-based diagnostics, the broadening of immuno-oncology pipelines, the expanding application of minimally invasive diagnostics, and a rise in healthcare spending allocated to cancer treatment. Key trends anticipated during the same period encompass the growing acceptance of targeted GI cancer therapies, an uptick in the utilization of molecular diagnostics, an intensified focus on immunotherapy combinations, the broadening of early cancer screening initiatives, and the improved incorporation of precision medicine.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Gastrointestinal Cancer Market?

The increasing embrace of targeted therapies is projected to fuel the expansion of the gastrointestinal cancer market moving forward. These treatments function by precisely hindering cancer cell proliferation through interaction with specific molecular targets, thereby minimizing harm to normal, healthy cells. Targeted therapies are designed to intervene in particular molecular pathways or genetic mutations that drive disease, especially in cancer. Unlike conventional treatments such as chemotherapy, which attack both healthy and diseased cells indiscriminately, targeted therapies concentrate on the distinct characteristics of a patient’s condition. For gastrointestinal (GI) cancer, these therapies act on specific genes or proteins that regulate tumor growth, offering precise and effective treatment. This yields superior outcomes with fewer side effects compared to traditional chemotherapy. For instance, in July 2023, as reported by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, the number of gene therapies in Phase II stood at 247 at the end of quarter one (Q1) 2023, subsequently rising by 5% to reach 260 by the end of quarter two (Q2). Thus, the growing adoption of targeted therapies is indeed propelling the growth of the gastrointestinal cancer market.

Which Segment Types Are Examined In The Gastrointestinal Cancer Market Segment Study?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

Which Trends Are Shaping The Gastrointestinal Cancer Market?

Leading companies in the gastrointestinal cancer market are concentrating on developing advanced solutions, such as monoclonal antibody treatment, to enhance patient survival rates and mitigate treatment-related adverse effects. Monoclonal antibody treatment involves the use of laboratory-produced antibodies designed to precisely identify and attach to cancer cells, thereby assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, following approval from the European Commission. This therapy is intended as a first-line treatment for adults diagnosed with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval positions VYLOY as the inaugural and sole therapy available in the European Union that targets CLDN18.2, a biomarker found in approximately 38% of these patients, supported by encouraging clinical trial data from the SPOTLIGHT and GLOW studies.

Which Players Are Part Of The Competitive Landscape Of The Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Get The Full Gastrointestinal Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Region Leads The Gastrointestinal Cancer Market In Terms Of Market Share?

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastrointestinal Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2026, By The Business Research Company

Colorectal Cancer Molecular Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Colorectal Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Gastrointestinal Cancer Market Evolve From 2026 To 2030?

The gastrointestinal cancer market has witnessed significant expansion in recent years. Its valuation is anticipated to grow from $27.05 billion in 2025 to $30.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.1%. The increase observed in the past can be ascribed to a rising prevalence of gastrointestinal cancers, the enhancement of diagnostic imaging capabilities, increased public awareness regarding early cancer detection, advancements in oncology drug development, and improved access to facilities for cancer treatment.

The gastrointestinal cancer market is projected to experience significant expansion in the coming years. Its valuation is set to reach $47.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This expansion during the forecast period is driven by factors such as greater investments in personalized oncology, the increasing embrace of biomarker-based diagnostics, the broadening of immuno-oncology treatment pipelines, an uptick in the utilization of minimally invasive diagnostics, and enhanced healthcare spending on cancer treatment. Key trends observed over this period encompass a wider acceptance of targeted GI cancer therapies, the growing application of molecular diagnostics, a heightened emphasis on combination immunotherapy approaches, the extension of early cancer screening initiatives, and improved integration of precision medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

What Drivers Are Influencing The Gastrointestinal Cancer Market?

The increasing embrace of targeted therapies is projected to fuel the expansion of the gastrointestinal cancer market in the coming years. These therapies represent treatments specifically designed to inhibit the proliferation of cancer cells by targeting particular molecular structures, thereby minimizing damage to healthy cells. Their mechanism involves acting on distinct molecular pathways or genetic alterations responsible for driving a disease, particularly in oncology. In contrast to conventional treatments such as chemotherapy, which indiscriminately affect both healthy and cancerous cells, targeted therapies concentrate on the specific attributes of a patient’s condition. For gastrointestinal (GI) cancer, targeted therapies operate on particular genes or proteins that regulate tumor development, leading to highly accurate and effective treatment. This approach yields improved results with fewer adverse reactions compared to standard chemotherapy. As an illustration, in July 2023, data from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, showed that at the close of quarter one (Q1) 2023, there were 247 gene therapies in Phase II, a figure that increased by 5% to reach 260 by the conclusion of quarter two (Q2). Consequently, the growing utilization of targeted therapies is propelling the growth of the gastrointestinal cancer market.

Which Segment Areas Are Covered In The Gastrointestinal Cancer Market Analysis?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

How Are Trends Shaping The Direction Of The Gastrointestinal Cancer Market?

Companies operating within the gastrointestinal cancer market are prioritizing the creation of advanced solutions, including monoclonal antibody treatment, to both enhance patient survival rates and mitigate treatment-related side effects. Monoclonal antibody treatment functions by utilizing laboratory-engineered antibodies that accurately identify and attach to cancer cells, thereby assisting the immune system in pinpointing and eradicating them. For instance, in September 2024, Japan-based pharmaceutical company Astellas Pharma Inc. released VYLOY (zolbetuximab) in conjunction with fluoropyrimidine- and platinum-containing chemotherapy, following its approval from the European Commission. This medication is designated as a first-line therapy for adults suffering from locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, provided their tumors express claudin 18.2 (CLDN18.2). This significant approval positions VYLOY as the initial and sole therapeutic option in the European Union specifically targeting CLDN18.2, a biomarker present in approximately 38% of such patients, based on compelling clinical trial outcomes from the SPOTLIGHT and GLOW studies.

Which Global Companies Are Actively Competing In The Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Read the full gastrointestinal cancer market report here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Gastrointestinal Cancer Market?

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastrointestinal Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2026, By The Business Research Company

Gastroesophageal Reflux Disease Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Gastroparesis Global Market Report

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Barretts Esophagus Global Market Report

https://www.thebusinessresearchcompany.com/report/barretts-esophagus-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model